Acrivon Therapeutics, INC Form 4 insider transactions

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 558 common stock shares to cover tax obligations upon vesting of restricted stock units.

RA Capital Management, L.P. and affiliated entities acquired 3,530,000 shares of Acrivon Therapeutics at $8.50 per share, increasing their total holdings.

Perceptive Advisors LLC, along with related entities, increased its holdings in Acrivon Therapeutics by purchasing 2,353,000 shares of common stock at $8.50 per share on April 11, 2024.

Director Santhosh Palani of Acrivon Therapeutics reports the acquisition of stock options.